Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUCMSC + NSC therapy for amyotrophic lateral sclerosis
ChiCTR1800017734Phase 2Not yet recruiting
- Sponsor
- Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
- Start
- Oct 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in amyotrophic lateral sclerosis (ALS), sponsored by Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine. Primary endpoints: ALS Functional Rating Scale-Revised, Myasthenia and muscular atrophy and 7 more. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ChiCTR1800017734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017734.